 "PLI scheme: Pharma industry expects more guidelines on investment")
The pharma industry felt the PLI scheme leads the way to create more global-scale pharma companies in India. The industry expects more guidelines to come out on minimum investment criterion to qualify for the scheme. If the Centre only links the incentive to incremental sales value, the industry is happy, said an industry insider.
Ramesh Swaminathan, chief financial officer and head of corporate affairs at Lupin, said, they are eagerly awaiting the finer details of the scheme. Meanwhile, B R Sikri, chairman of the Federation of Pharma Entrepreneurs, said, higher incentives would have meant more production of cancer drugs, thereby, bringing down their prices.
The large pharma firms are keen to take part in the scheme, says Sudarshan Jain, secretary general of the Indian Pharmaceutical Alliance, that represents the country’s largest 24 pharma firms.
Ramesh Swaminathan, chief financial officer and head of corporate affairs at Lupin, said, they are eagerly awaiting the finer details of the scheme. Meanwhile, B R Sikri, chairman of the Federation of Pharma Entrepreneurs, said, higher incentives would have meant more production of cancer drugs, thereby, bringing down their prices.
The large pharma firms are keen to take part in the scheme, says Sudarshan Jain, secretary general of the Indian Pharmaceutical Alliance, that represents the country’s largest 24 pharma firms.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%